Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Purchased by Virtus ETF Advisers LLC

Virtus ETF Advisers LLC lifted its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 43.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,597 shares of the company’s stock after acquiring an additional 9,494 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Taysha Gene Therapies were worth $55,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in TSHA. Barclays PLC grew its position in shares of Taysha Gene Therapies by 356.0% in the 3rd quarter. Barclays PLC now owns 247,280 shares of the company’s stock worth $513,000 after acquiring an additional 193,046 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Taysha Gene Therapies by 23.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after acquiring an additional 682,273 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of Taysha Gene Therapies in the 3rd quarter worth approximately $201,000. JPMorgan Chase & Co. boosted its position in Taysha Gene Therapies by 1.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,001,397 shares of the company’s stock valued at $6,033,000 after purchasing an additional 37,844 shares during the period. Finally, Quantum Private Wealth LLC boosted its position in Taysha Gene Therapies by 3.6% during the 4th quarter. Quantum Private Wealth LLC now owns 794,976 shares of the company’s stock valued at $1,375,000 after purchasing an additional 27,360 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Chardan Capital restated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Monday. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Monday. Finally, Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, April 10th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Stock Performance

Shares of TSHA opened at $1.80 on Tuesday. The firm has a 50-day moving average price of $1.55 and a 200 day moving average price of $1.80. The firm has a market capitalization of $369.10 million, a PE ratio of 2.86 and a beta of 0.96. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The firm had revenue of $2.02 million during the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. On average, sell-side analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.